Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance
- 187 Downloads
Glucagon-like peptide–1 receptor agonists (GLP-1RAs) are categorized as short- or long-acting types, but information regarding differences in the effects of these two types on postprandial glucose disposal has been limited. We have now investigated the effects of exenatide and liraglutide (short- and long-acting GLP-1RAs, respectively) on glucose disposal during an oral glucose tolerance test (OGTT).
Fourteen healthy volunteers with normal glucose tolerance underwent three OGTTs, which were performed without pharmacological intervention or after a single administration of exenatide or liraglutide at 30 min and 10 h, respectively, before test initiation. The three OGTTs were performed with intervals of at least 7 days between successive tests and within a period of 2 months.
Exenatide, but not liraglutide, markedly decelerated the peak of both plasma glucose and serum insulin levels during the OGTT, with the peaks of both glucose and insulin concentrations occurring at 150 min after test initiation with exenatide compared with 30 min in the control condition or with liraglutide. Exenatide and liraglutide reduced the area under the curve for plasma glucose levels during the OGTT by similar extents, whereas that for serum insulin levels was reduced only by exenatide.
Our results suggest that exenatide decelerates the increase in plasma glucose levels through inhibition of glucose absorption and that it exerts an insulin-sparing action after glucose challenge.
KeywordsExenatide Liraglutide Oral glucose tolerance test Japanese
We thank Yuki Nishimoto, Kei Yoshino, Takehito Takeuchi, Hiroshi Miura, and Yasushi Nakagawa for assistance with data collection.
Compliance with ethical standards
Conflict of interest
T.M., K.S., and W.O. have received lecture fees from Novo Nordisk; Y.H., K.S., and W.O. have received lecture fees from Eli Lilly; and Y.H. and W.O. have received lecture fees from Astra Zeneca. W.O. has received research support from Novo Nordisk, Eli Lilly, and Astra Zeneca.
This exploratory, open-label, single-center study was approved by the ethics committee of Kobe University Graduate School of Medicine (approval no. 230021), conforms to the provisions of the Declaration of Helsinki, and is registered in the University Hospital Medical Information Network (UMIN000006858).
All the individuals provided written informed consent to participation in the study.
- 5.S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse; LEADER Steering Committee; LEADER Trial Investigators, Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016)CrossRefGoogle Scholar
- 6.S.P. Marso, S.C. Bain, A. Consoli, F.G. Eliaschewitz, E. Jódar, L.A. Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M.L. Warren, V. Woo, O. Hansen, A.G. Holst, J. Pettersson, T. Vilsbøll; SUSTAIN-6 Investigators, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016)CrossRefGoogle Scholar
- 10.J.J. Meier, B. Gallwitz, S. Salmen, O. Goetze, J.J. Holst, W.E. Schmidt, M.A. Nauck, Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 2719–2725 (2003)CrossRefGoogle Scholar
- 13.M.D. Turton, D. O’Shea, I. Gunn, S.A. Beak, C.M. Edwards, K. Meeran, S.J. Choi, G.M. Taylor, M.M. Heath, P.D. Lambert, J.P. Wilding, D.M. Smith, M.A. Ghatei, J. Herbert, S.R. Bloom, A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69–72 (1996)CrossRefGoogle Scholar
- 15.C.W. le Roux, A. Astrup, K. Fujioka, F. Greenway, D.C.W. Lau, L. Van Gaal, R.V. Ortiz, J.P.H. Wilding, T.V. Skjøth, L.S. Manning, X. Pi-Sunyer; SCALE Obesity Prediabetes NN8022-1839 Study Group, 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389, 1399–1409 (2017)CrossRefGoogle Scholar
- 17.J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J.H. Brett, M. Zychma, L. Blonde; LEAD-6 Study Group, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39–47 (2009)CrossRefGoogle Scholar
- 18.C. Kapitza, T. Forst, H.V. Coester, F. Poitiers, P. Ruus, A. Hincelin-Méry, Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes. Metab. 15, 642–649 (2013)CrossRefGoogle Scholar
- 20.P.A. Kothare, H. Linnebjerg, Y. Isaka, K. Uenaka, A. Yamamura, K.P. Yeo, A. de la Peña, C.H. Teng, K. Mace, M. Fineman, H. Shigeta, Y. Sakata, S. Irie, Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J. Clin. Pharmacol. 48, 1389–1399 (2008)CrossRefGoogle Scholar
- 21.S. Kageyama, K. Hirao, A. Shimizu, Y. Matsumura, M. Zdravkovic, M.F. Rasmussen, S. Irie, Tolerability, pharmacokinetics, and pharmacodynamics of liraglutide, long-acting human GLP-1 analogue―phase I studies in Japanese healthy subjects and subjects with type 2 diabetes. Endocrinol. Diabetol. 24, 95–104 (2007). [in Japanese]Google Scholar
- 22.S.S. Thazhath, C.S. Marathe, T. Wu, J. Chang, J. Khoo, P. Kuo, H.L. Checklin, M.J. Bound, R.S. Rigda, B. Crouch, K.L. Jones, M. Horowitz, C.K. Rayner, The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial. Diabetes 65, 269–275 (2016)Google Scholar